PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Drug Alcohol Depend. Author manuscript; available in PMC 2010 May 27.
Published in final edited form as:
PMCID: PMC2877623
NIHMSID: NIHMS205769

Huntington disease as a dual diagnosis disorder: Data from the national research roster for Huntington disease patients and families

Abstract

Although an extensive literature characterizes a linkage between primary mental illnesses and substance use disorders, a paucity of research exists concerning dual diagnosis phenomena in Huntington disease (HD). Data from the National Research Roster on HD suggest that higher levels of alcohol and cigarette use are associated with greater ratings of psychiatric symptoms and a younger age of HD symptom onset, and that progressive alcohol use after HD symptom onset is linked with worsening psychiatric symptom progression. These findings suggest HD entails dual diagnosis phenomena similar to that identified in patients with primary psychiatric disorders.

Keywords: Huntington disease, Dual daignosis, Alcohol, Nicotine, Psychiatric symptoms

1. Introduction

Huntington disease (HD) is an autosomal dominant neuropsychiatric disorder with onset ranging over the lifespan, and prevalence of 4–8 per 100,000 (Di Maio et al., 1993; Harper, 1992). Psychiatric manifestations occur more frequently in HD than other dementias and basal ganglia disorders, and often resemble schizophrenia, bipolar, and unipolar syndromes, obsessive–compulsive disorder, or their variants (Anderson et al., 2001; Folstein and Folstein, 1983; Mendez, 1994). HD causes progressive atrophy and neuronal loss in cortical-striatal circuits corresponding to a progressive triad of motor, cognitive, and psychiatric symptoms (Cummings, 1993; Halliday et al., 1998; Joel, 2001; Litvan et al., 1998; Paulsen et al., 2001; Thieben et al., 2002; Vonsattel et al., 1985)].

Cortical-striatal circuits are also implicated in non-HD based psychiatric disorders including substance use disorders (SUDS), schizophrenia, bipolar and unipolar disorders (Chambers et al., 2001; Swerdlow and Koob, 1987). These disorders and SUDs are frequently cormorbid (Kessler, 2004), possibly as a result of overlapping cortical-striatal circuit involvement mediating mental illness and SUDs (Chambers et al., 2001). Although these data and anecdotal reports suggest SUDs and HD could also be linked, studies exploring this association are scarce (Lopez and Jeste, 1997). Only one report directly examines alcohol SUDs in a clinical sample (King, 1985). To our knowledge, there are no studies examining smoking in HD.

The National Research Roster for Huntington Disease Patients and Families at Indiana University ranks among the largest data bases on HD. Here, we report the first examination of the roster for alcohol and cigarette use, psychiatric symptom severity, age at HD onset, and psychiatric symptom progression.

2. Methods

Since 1979, HD patients and families have voluntarily contacted the roster after becoming aware by brochures, the internet and other sources. Respondents sign informed consent, authorization to release information (approved by Indiana University IRB), and fill out a 13 page questionnaire gathering general information, and illness history. The questionnaire serves a broad array of potential research questions concerning HD natural course, associated factors, and impact, and was not programmed with respect to any particular hypothesis. Questionnaires are completed by first degree relatives (87%) and self report (4%).

The questionnaire states “The symptoms of HD and the age at which they appear differ greatly from individual to individual”. Its then asks “At what age did the symptoms first appear?” Substance use and psychiatric symptom ratings before and after HD onset are then ascertained. Four forms of substance use are addressed: ‘alcohol’, ‘cigarettes’, “tranquilizers”, and ‘non-prescribed drugs’. Due to the ambiguity of the latter terms, only cigarette and alcohol use were examined. Responders rate subject’s alcohol and cigarette use: 1 (“not at all”); 2 (“light use”); 3 (“moderate use”); 4 (“heavy use”); 5 DK (“Don’t Know”). They also rate, from 1 (“doesn’t describe”) to 5 (“describes very well”), each of 10 negatively valenced affective characteristics (sad, nervous, worried, listless, depressed, angry, suspicious, irritable, moody, and quarrelsome) and each of three positively valenced characteristics (happy, calm, and energetic).

In examining substance use patterns, psychiatric symptom severity, and age of HD onset, cases were sub-grouped into four categories of substance use: (1) low alcohol/low cigarette use; (2) high alcohol/low cigarette use; (3) low alcohol/high cigarette use; and (4) high cigarette/high alcohol use. Reports of 1 (not at all) and 2 (light use) were ranked low use and reports of 3 (moderate use) or 4 (heavy use) were deemed high use. From among the 13 affective characteristics, the 10 negative affective ratings were summed to create a ‘pathological’ psychiatric rating (scores ranging 10–50), and the three positive ratings were summed to a ‘desirable’ psychiatric rating (ranging 3–15).

For assessing substance use and psychiatric symptom progression, subjects were re-classified with respect to alcohol and cigarettes independently by whether use increased, was unchanged, or decreased after HD onset. These groups were then compared with respect to change in pathological and desirable psychiatric ratings after HD onset.

Consistent with prior studies using the roster (Kirkwood et al., 2001) juvenile onset HD cases (<20 years of age) were excluded reducing the data base from 2556 to 2303 cases. To work with the largest amount of data, further exclusions for missing data took place on an analysis by analysis basis.

Analysis of substance use groupings (independent factor) and psychiatric ratings, age of HD onset, and change in psychiatric ratings (dependent measures) entailed separate one-way analyses of variance (ANOVAs). Kurtosis and skewness ranged between {−1 and 1.1} for all subgroup distributions where ANOVAs were applied. Significance was identified at p < 0.05 and means are presented with standard deviations.

3. Results

The pool of 2303 cases included patients from all 50 states and the District of Columbia. Caucasians comprised 98% of this sample with 51.1% female and 48.9% male. Rigid and choreic forms of HD were reported in 3.7% and 69.2% while 27.1% answered “Don’t Know” or were missing. Average age at HD onset was 41.4 ± 10.8, with mean birth year of 1923.7 ± 17.3 (16 of 2303 cases missing birth year).

From the sample of 2303 cases, 1976 answered questions needed for examining alcohol/cigarette use, psychiatric ratings, or age of HD onset. Table 1, upper panel, shows demographics of the four substance use groups categorized by degree of alcohol/cigarette use. 50.8% comprised the low alcohol/low cigarette use group; 9.1%, high alcohol/low cigarette; 20.6%, low alcohol/high cigarette; and 19.5%, high alcohol/high cigarette use.

Table 1
Demographics (upper panel) of four substance use groupings, and analysis of HD psychiatric ratings and age of onset (lower panel)

Of the 1976 cases, 1060 responded to all pathological ratings after symptom onset, and 1381 responded to the three desirable ratings (Table 1, lower panel). The pathological ratings varied significantly between substance use groups (F = 4.13, d.f. = 3, 1059, p < 0.01), and generally increased in order of increasing alcohol/nicotine use. A separate ANOVA revealed no significant differences between substance use groups in terms of desirable ratings.

All 1976 subjects reported age at symptom onset which varied significantly between substance use groups (F = 3.48, d.f. = 3, 1975, p < 0.05). Here, the same substance use group ordering identified in the pathological ratings was ordered by decreasing age at HD onset.

From the sample of 2303 cases, 1851 responded sufficiently for detecting changes in alcohol use, and 2021 for cigarette use. Table 2, upper panel shows demographics of these groupings. For alcohol, 32% decreased, 59% unchanged, and 8.6% increased use; for cigarettes 1.2% decreased, 98% unchanged, and 0.6% increased use.

Table 2
Demographics (upper panel) of the groups by change in substance use after HD onset, and analysis of change in psychiatric ratings after HD onset (lower panel)

Of cases grouped by change in substance use, 954 from the alcohol and 988 from the cigarette grouping responded to all 10 pathological characteristics ratings before and after symptom onset (Table 2, lower panel). Groupings by changes in alcohol use varied significantly by changes in pathological ratings (F = 7.76, d.f. = 2, 953, p < 0.001); subjects with increased alcohol use had the largest increase in pathological ratings. Similar non-significant trends were observed in terms of cigarette use. Changes in patterns of alcohol or cigarette use had no impact on declining desirable ratings after HD onset.

4. Discussion

These findings suggest substance use and severity of psychiatric symptoms are associated in HD, whether in terms of combined alcohol and cigarette use, or progressive changes in alcohol use and psychiatric symptom course. Given that younger HD onset is associated with greater genetic and clinical liability to HD (Currier et al., 1982; Mahant et al., 2003; Marder et al., 2000), greater substance use in HD patients with younger age of onset also supports this association. Taken together, these findings are consistent with the possibility of synergistic disease processes of HD and SUDS involving common cortical-striatal circuits.

Without matched control groups, the results cannot define increased risk of SUDs in HD. However, 40% and 29% of the sample were rated as high nicotine and/or high alcohol users respectively. By comparison, 26.5% of U.S. adults aged 18 or older in 1992 were smokers (CDC, 1994). For subjects in the HD roster reporting disease onset in 1992 or after, 41% were rated as moderate or high smokers. Greater frequencies of hospitalization for alcoholism (Jensen et al., 1993) and drunk driving offences (Jensen et al., 1998) have been observed in HD patients compared to at-risk controls, while another study found alcohol abuse/dependence in HD comparable to the general population at rates of 24% for males and 5.9% for females (King, 1985). The present study also identified higher levels of alcohol and/or cigarette use in male compared to female HD patients (Table 1), consistent with most studies on gender ratios of SUDs in the general population (Brady and Randall, 1999).

As an exploration using the HD roster, this study has considerable methodological limitations. The data represents a polling of family members, using non-validated, non-standardized research instruments subject to several potential response or selection biases and subjective weighting. Retrospective estimates of disease onset and illness course are difficult for professionals and lay-persons, and objective measures of HD disease provided by genetic or cognitive testing were unavailable. Nevertheless, this study suggests the need for greater attention to the prevalence, impact, and treatment of SUDs in HD. Given the similarity of these findings to studies on primary psychiatric syndromes where SUDs seem particularly associated with male gender, greater psychiatric morbidity, and earlier age of illness onset (Cantwell et al., 1999; Dixon, 1999; RachBeisel et al., 1999; Siegfried, 1998), further research on HD as a dual diagnosis condition with relatively well-defined genetic and neurobiological origins is warranted.

Acknowledgements

This work was supported by National Institutes of Health (NIH No1-NS-3-2357) (PSD) and the National Institute of Drug Abuse (K08 DA019850-01) (RAC).

References

  • Anderson KE, Louis ED, Stern Y, Marder KS. Cognitive correlates of obsessive and compulsive symptoms in Huntington’s disease. Am. J. Psychiat. 2001;158:799–801. [PubMed]
  • Brady KT, Randall CL. Gender differences in substance use disorders. Psychiat. Clin. N. Am. 1999;22:241–252. [PubMed]
  • Cantwell R, Brewin J, Glazebrook C, Dalkin T, Fox R, Medley I, Harrison G. Prevalence of substance misuse in first-episode psychosis. Br. J. Psychiat. 1999;164:150–153. [PubMed]
  • CDC Cigarette smoking among adults, United States, 1992, and changes in the definition of current cigarette smoking. MMWR. 1992;43:342–346. [PubMed]
  • Chambers RA, Krystal JK, Self DW. A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol. Psychiat. 2001;50:71–83. [PMC free article] [PubMed]
  • Cummings JL. Frontal-subcortical circuits and human behavior. Arch. Neurol. 1993;50:873–880. [PubMed]
  • Currier RD, Jackson JF, Meydrech EF. Progression rate and age at onset are related in autosomal dominant neurological diseases. Neurology. 1982;32:907–909. [PubMed]
  • Di Maio L, Squitieri F, Napolitano G, Campanella G, Trofatter JA, Conneally PM. Onset symptoms in 510 patients with Huntington’s disease. J. Med. Genetics. 1993;30:289–292. [PMC free article] [PubMed]
  • Dixon L. Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes. Schizophr. Res. 1999;35(Suppl.):93–100. [PubMed]
  • Folstein SE, Folstein MF. Psychiatric feature of Huntington’s disease: recent approaches and findings. Psychiat. Develop. 1983;2:193–206. [PubMed]
  • Halliday GM, McRitchie DA, Macdonald V, Double KL, Trent RJ, McCusker E. Regional specificity of brain atrophy in Huntington’s disease. Exp. Neurol. 1998;154:663–672. [PubMed]
  • Harper PS. The epidemiology of Huntington’s disease. Human Genetics. 1992;89:365–376. [PubMed]
  • Jensen P, Fenger K, Bolwig TG, Sorenson SA. Crime in Huntington’s disease: a study of registered offences among patients, relatives, and controls. J. Neurol. Neurosurg. Psychiat. 1998;65:467–471. [PMC free article] [PubMed]
  • Jensen P, Sorenson SA, Fenger K, Bolwig TG. A study of psychiatric morbidity in patients with Huntington’s disease: their relatives, and controls. Br. J. Psychiat. 1993;163:790–797. [PubMed]
  • Joel D. Open interconnected model of basal ganglia-thalamocortical circuitry and its relevance to the clinical syndrome of Huntington’s disease. Movement Disord. 2001;16:407–423. [PubMed]
  • Kessler RC. The epidemiology of dual diagnosis. Biol. Psychiat. 2004;56:730–737. [PubMed]
  • King M. Alcohol abuse in Huntington’s disease. Psychol. Med. 1985;15:815–819. [PubMed]
  • Kirkwood SC, Su JL, Conneally PM, Foroud T. Progression of symptoms in the early and middle stages of Huntington disease. Arch. Neurol. 2001;58:273–278. [PubMed]
  • Litvan I, Paulsen JS, Mega MS. Neuropsychiatric assessment of patients with hyperkinetic and hypokinetic movement disorders. Arch. Neurol. 1998;55:1313–1319. [PubMed]
  • Lopez W, Jeste DV. Movement disorders and substance abuse. Psychiat. Serv. 1997;48:634–636. [PubMed]
  • Mahant N, McCusker EA, Byth K, Graham S, Group HS. Huntington’s disease clinical correlates of disability and progression. Neurology. 2003;61:1085–1092. [PubMed]
  • Marder K, Zhao H, Myers RH, Cudkpwicz M, Kayson E, Kieburtz K, Orme C, Penney JB, Siemers E, Shoulson I, Group HS. Rate of functional decline in Huntington’s disease. Neurology. 2000;54:452–458. [PubMed]
  • Mendez MF. Huntington’s disease: update and review of neuropsychiatric aspects. Int. J. Psychiat. Med. 1994;24:189–208. [PubMed]
  • Paulsen JS, Zhao H, Stout JC, Brinkman RR, Guttman M, Ross CA, Como R, Manning C, Hayden MR, Shoulson I, Huntington Study Group Clinical markers of early disease in persons near onset of Huntington’s disease. Neurology. 2001;57:658–662. [PubMed]
  • RachBeisel J, Scott J, Dixon L. Co-occurring severe mental illness and substance use disorders: a review of recent research. Psychiat. Serv. 1999;50:1427–1434. [PubMed]
  • Siegfried N. A review of comorbidity: major mental illness and problematic substance use. Aust. NZ J. Psychiat. 1998;32:707–717. [PubMed]
  • Swerdlow NR, Koob GF. Dopamine, schizophrenia, mania and depression: toward a unified hypothesis of cortico-striato-pallido-thalamic function. Behav. Brain Sci. 1987;10:197–245.
  • Thieben MJ, Duggins AJ, Good CD, Gomes L, Mhant N, Richards F, McCusker E, Frackowiak RSJ. The distribution of structural neuropathology in pre-clinical Hunitngton’s disease. Brain. 2002;125:1815–1828. [PubMed]
  • Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP., Jr. Neuropathological classification of Huntington’s disease. J. Neuropathol. Exp. Neurol. 1985;44:559–577. [PubMed]